A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Ellence Patient, Information, Instructions - Epirubicin hydrochloride
Ellence Patient, Information, Instructions - Epirubicin hydrochloride
PATIENT INFORMATION
Patients should be informed of the expected adverse effects
of epirubicin, including gastrointestinal symptoms (nausea, vomiting, diarrhea,
and stomatitis) and potential neutropenic complications. Patients should consult
their physician if vomiting, dehydration, fever, evidence of infection, symptoms
of CHF, or injection-site pain occurs following therapy with ELLENCE. Patients
should be informed that they will almost certainly develop alopecia. Patients
should be advised that their urine may appear red for 1 to 2 days after administration
of ELLENCE and that they should not be alarmed. Patients should understand that
there is a risk of irreversible myocardial damage associated with treatment
with ELLENCE, as well as a risk of treatment-related leukemia. Because epirubicin
may induce chromosomal damage in sperm, men undergoing treatment with ELLENCE
should use effective contraceptive methods. Women treated with ELLENCE may develop
irreversible amenorrhea, or premature menopause.
Laboratory Testing
See WARNINGS. Blood counts,
including absolute neutrophil counts and liver function should be assessed before
and during each cycle of therapy with epirubicin. Repeated evaluations of LVEF
should be performed during therapy.
top
